1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69222A7BD3557F4FF652584F80026D672
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/maximizing-impact-medical-affairs-oncology-product-launches?opendocument
18
19opendocument
2018.97.14.85
21
22
23best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Launch Optimization

Maximizing the Impact of Medical Affairs in Oncology Product Launches

ID: POP-322


Features:

34 Info Graphics

26 Data Graphics

540+ Metrics


Pages: 77


Published: 2020


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
The rapid pace of innovation in oncology therapeutics has led to intense competition between pharma companies to successfully launch their new products into the market. And as a key conduit between pharma organizations and critical decision makers, the Medical Affairs function drives many of the vital activities that span the critical periods of pre-launch, launch and post-launch - all of which can help determine the ultimate success of a new cancer treatment.

Best Practices, LLC undertook this benchmarking research to explore how savvy Medical Affairs teams can deliver high-caliber, measurable value to each of their organization's oncology product launches.

This report provides insights and benchmarks around Medical Affairs’ role, activities and timelines, cross-functional collaboration, strategy planning, staffing, budgeting, preparedness metrics, tools and technology for a successful oncology product launch. This report also identifies the critical success factors and major pitfalls for Medical Affairs during oncology product launch.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Chemical; Health Care; Diagnostic; Medical Device


Companies Profiled:
AbbVie; Alkermes; AstraZeneca; Boehringer Ingelheim; Celgene; Cipla; Clovis Oncology; Crescendo Bioscience; Curis; Daiichi Sankyo; Eisai; Exelixis ; GRAIL; Merck; Merck KGaA; Novartis; Roche; Sandoz; Sanofi Genzyme; Servier; Shire; Taiho Oncology; Takeda Pharmaceuticals; Torrent Pharmaceuticals Ltd.; Zydus Cadila

Study Snapshot

Best Practices, LLC engaged over 35 oncology Medical Affairs experts from 25 pharmaceutical and biotechnology companies in this research study through a benchmarking survey, interviews and a roundtable discussion.

Key topics covered in this report include:

  • Oncology Launch Strategy and Work Plan
  • Oncology Launch Timeline Overview
  • Oncology Launch Resourcing
  • Oncology Launch Enablers


Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Develop, deploy and stick to a launch timeline: Use launch roadmap to coordinate the Medical Affairs activities with other functions, understand interdependencies, and which activities to prioritize and where to allocate funding

    • Develop timeline for critical launch activities around strategy, research, communications, data generation and other activities. Specify discrete and continuous activities.
    • Have a full Medical Affairs team 18-24 months before the launch, including securing the Medical Affairs field resources, leadership and project management milestones.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Launch Strategy and Work Plan7
Medical Affairs Role and Activity Effectiveness15
Ensuring Cross-functional Alignment and Collaboration20
Adapting to Ongoing Changes in Medical Affairs Landscape24
Medical Affairs Leading vs. Supporting Brand Teams29
II.
Launch Timeline Overview35
Launch Timeline Details37
III.
Launch Resourcing45
IV.
Launch Enablers50
Technology50
Launch Preparedness Metrics53
Critical Success Factors and Major Pitfall58
V.
Appendix63
Medical Affairs Role and Activity Effectiveness63
Launch Timeline70
Glossary75

    List of Charts & Exhibits

    I. Launch Strategy and Work Plan

    • Structuring the oncology launch framework
    • Laying the groundwork for Medical Affairs oncology launch excellence
    • Understanding the oncology disease landscape
    • Setting medical strategic imperatives: Oncology launch value pyramid
    • Setting aspirational behaviors for key stakeholders
    • Planning oncology stakeholder engagement
    • Planning resourcing and facilitating cross-functional collaboration

    I A . Medical Affairs Role and Activity Effectiveness

    • Growth in Medical Affairs’ role across multiple oncology areas in recent years
    • Lead and support role of Medical Affairs in oncology therapeutic area
    • Medical Affairs’ effectiveness in oncology launch activities

    I B . Ensuring Cross-functional Alignment and Collaboration

    • Collaboration with internal groups to ensure successful oncology launch
    • Medical Affairs’ role in cross-functional teams
    • Tactics to improve cross-functional collaboration and work alignment in oncology

    I C . Adapting to Ongoing Changes in Medical Affairs Landscape

    • Medical Affairs’ focus area
    • Change in Medical Affairs’ oncology launch role within the last 3 years – Research and data generation
    • Change in Medical Affairs’ oncology launch role within the last 3 years – Data dissemination and communication
    • Change in Medical Affairs’ oncology launch role within the last 3 years – Education and Organizational support

    I D . Medical Affairs Leading vs. Supporting Launch Teams

    • Medical Affairs’ role in cross-functional oncology launch teams
    • Leading/co-leading and supporting role played by Medical Affairs in different launch-related activities
    • Oncology launch phase in which Medical Affairs groups lead/co-lead or support activities
    • Major pitfalls encountered by Medical Affairs during oncology launch
    • Drivers and benefits of leading/co-leading brand launch team in oncology

    II. Launch Timeline Overview

    • Actual vs. ideal time to start oncology launch activities


    II A . Launch Timeline Details

    • Oncology launch timeline – Planning and budgeting Medical Affairs work
    • Oncology launch timeline – Building Medical Affairs team and deploying progress trackers
    • Oncology launch timeline – Organizational support and data generation
    • Oncology launch timeline – Education and advisory boards
    • Oncology launch timeline – Leading internal communication and building medical data
    • Oncology launch timeline – Publications and medical congresses
    • Oncology launch timeline – Engaging key external stakeholders

    III. Launch Resourcing

    • Medical Affairs staffing and investment breakdown before and post launch
    • Medical Affairs oncology launch investment per medical FTE
    • Before and post launch budget allocation for key oncology activities
    • Before and post launch staffing allocation for key oncology activities

    IV. Launch Enablers

    IV A . Technology

    • Communication and materials building tools used by Medical Affairs during oncology launch and their relative popularity
    • CRM and collaboration tools used by Medical Affairs during oncology launch and their relative popularity

    IV B . Launch Preparedness Metrics

    • Existence of oncology launch dashboard at benchmark companies and reported metrics usage by category type
    • Potential oncology drug launch metrics (reported & Best Practices generated) – Strategy planning, project management, education and organizational support
    • Potential oncology drug launch metrics (reported & Best Practices generated) – Communications and stakeholder engagement
    • Potential oncology drug launch metrics (reported & Best Practices generated) – Stakeholder engagement

    IV C . Critical Success Factors and Major Pitfalls

    • Critical factors that drive successful oncology launches for Medical Affairs
    • Six steps to a stronger oncology launch
    • Major pitfalls for Medical Affairs during oncology launch
    • Six pitfall areas in oncology launch

    V. Appendix

    • Medical Affairs’ role in oncology launch planning and research activities
    • Medical Affairs’ role in education, data dissemination and organizational support activities
    • Effectiveness of launch research activities
    • Effectiveness of education activities
    • Effectiveness of communication and data dissemination activities
    • Effectiveness of Medical Affairs organizational support activities
    • Involvement of Medical Affairs in evidence generation and FBM related oncology launch activities
    • Involvement of Medical Affairs in medical information and regulatory related oncology launch activities
    • Involvement of Medical Affairs in HEOR and medical/scientific communication related oncology launch activities
    • Involvement of Medical Affairs in independent medical education and external engagement/collaboration related oncology launch activities
    • Glossary